Ad copy

I've worked in psychiatry for 11 years. Nine months ago, I stopped recommending SSRIs as a first response to patients describing flatness, lost motivation, and zero drive. I'm going to tell you what I found. And you're going to want to think about this before your next appointment. It started at my desk at 7 PM on a Tuesday. I'd just finished a session with a patient I'd been seeing for three years. Brilliant woman. Methodical. Did everything right. Took every medication I'd suggested. Adjusted every dose when I asked. Showed up to every session. And sat across from me describing the exact same flatness she'd described in our first session in 2021. Not sadness. Not crisis. Flatness. Lost motivation. The inability to feel genuinely rewarded by her own life. The sense of watching it from slightly outside. Her serotonin was stabilized. Her SSRI was doing exactly what it was designed to do. The problem she was actually describing had never been addressed. I sat at my desk that night and started reading. What I found changed how I practice. The serotonin hypothesis. That's the framework underlying virtually every antidepressant prescribed in the United States. SSRIs. SNRIs. The medications on 37 million Americans' daily schedules. Here's what the framework actually addresses. SSRIs inhibit the reuptake of serotonin. More serotonin stays available in the synapse. Mood stability improves. Anxiety softens. For a significant portion of patients, this is meaningful help. Let me tell you what it does not address. Dopamine. A completely different neurotransmitter. A completely different system. A completely different set of functions. Serotonin governs mood stability, anxiety, and emotional regulation. Dopamine governs motivation, drive, the anticipation of reward, the ability to feel excited about your future, the pull toward things you care about, the satisfaction of finishing something, the sense that life has color. These are not the same system. They are not interchangeable. When a patient comes to me describing flatness, lost motivation, anhedonia, and the inability to feel present in their own life — those symptoms are primarily dopamine phenomena. And the medications I was trained to reach for first are serotonin medications. I had been treating the wrong signaling pathway for years. Not because I was a bad clinician. Because the training pointed one direction and the pharmaceutical infrastructure built around that training pointed the same direction. But it gets worse. Dopamine doesn't just decline with mood. It declines with age. Starting in the mid-40s, and accelerating sharply after 55, dopamine receptor density drops 3 to 14 percent every single decade. The brain's capacity to produce sufficient dopamine for motivation, drive, and reward literally diminishes as we age. This is not a finding that has been integrated into standard psychiatric practice. The patient sitting across from me at 55 or 60 or 65, describing flatness and lost motivation — the conversation almost never touches the progressive dopamine decline happening in their brain. We reach for the serotonin prescription. We adjust. We switch. We add therapy. The dopamine system depletes in the background. Unchallenged. For years. Let me tell you what those numbers actually mean. At the dopamine depletion levels typical for someone in their late 50s, the brain cannot sustain the motivation to initiate things. Cannot sustain the reward signal that makes effort feel worthwhile. Cannot sustain the anticipatory excitement that makes the future feel worth orienting toward. These are not symptoms of weakness or character failure. These are measurable neurochemical deficits. And an SSRI does not touch them. Not at any dose. Not combined with any therapy. Not with any adjustment. Because the SSRI is designed for a different system. This is not a defect in the medication. This is not a prescribing error. This is the design. The entire antidepressant industry builds products to address the serotonin pathway. Not because that's where every presentation of low mood originates. Not because it's the system most implicated in the flatness and lost motivation that brings most adults over 55 into my office. But because that's the system that produced the most patentable compounds in the 1980s and 1990s, and the framework built around those compounds became the standard of care. That's the infrastructure. Serotonin. Adjusted. Switched. Combined. Added to. And that certification of treatment — that documented prescription history — is in the charts of millions of people who are still flat. After I read all of this, I looked up from my desk. My patient's chart was still open. Three years of SSRI treatment. Three years of adjustments. Three years of the same flat presentation at the end of every session. Not because we hadn't tried. Because we'd been trying on the wrong system. If her dopamine system had been declining since she was in her early 50s, here's what would have been happening in my office. She would describe flatness. I would hear low mood. I would reach for serotonin. The medication would address serotonin. The dopamine system would keep declining. She would return in three months. Describe the same flatness. I would adjust the serotonin medication. The dopamine system would keep declining. She would tell me the anxiety was better. I would note improvement. The core of what she was actually describing — the motivation, the drive, the lost reward signal — would remain untouched. Three years later, she would sit across from me and describe the same flatness she described in session one. That's not a hypothetical. That's the chart open on my desk. And it plays out in my office more than I want to acknowledge. A colleague, Dr. Chen, mentioned she'd been incorporating dopamine precursor support into treatment for patients with this specific profile. Not instead of medication — alongside it, and then tapering medication where appropriate under supervision. She was using a transdermal patch delivering three compounds: Mucuna Pruriens for direct L-DOPA — the actual precursor the brain converts into dopamine. Rhodiola Rosea for cortisol modulation — because elevated cortisol actively suppresses dopamine production and they compete for the same pathway. Lion's Mane for Nerve Growth Factor — supporting the neurons that carry dopamine signals. Transdermal. Not oral. Because oral Mucuna faces first-pass liver metabolism — the L-DOPA is largely converted to dopamine in the periphery before it reaches the brain. Transdermal delivery bypasses this. The compounds arrive intact. "The patients who respond are the ones describing exactly what your patient describes," she said. "Flatness. Lost motivation. Anhedonia. The ones the SSRI helped but didn't reach." I started recommending it. Not as a replacement for clinical care. Not without monitoring. Not for every presentation. But for the patient sitting across from me describing motivation loss, drive deficit, and flatness that three years of serotonin management hadn't touched — I started recommending it. And the outcomes were different. The first patient I referred came back six weeks later describing something she hadn't described in three years of treatment. She'd initiated something. Not because I assigned it. Not because she was doing the homework. Because she wanted to. The gap between what she was doing and what she felt while doing it had closed. The reward signal was working. Not perfectly. Not completely. But directionally, for the first time in years, things were moving. The antidepressant industry built a treatment pathway that addresses the legal and clinical definition of depression. The dopamine system builds the experience of actually living your life. Those are not the same thing. If you have been in treatment for low mood, flatness, or lost motivation — and there's a significant chance you have — your treatment is almost certainly built around serotonin. It may be doing exactly what it was designed to do. And the system most responsible for your motivation, your drive, and your ability to feel genuinely present in your own life may never have been addressed. It's not protecting your sense of being alive at the levels that matter. It's addressing the system that was easiest to patent. I linked the product Dr. Chen referenced below. The only one I've found that delivers all three compounds transdermally in clinical form. All natural. Made in the United States. GMP certified. Full money-back guarantee. https://veliza.shop/products/veliza-dopamine-patches